Compugen to Present Data on COM701, COM902, Pembrolizumab Combo in Platinum-Resistant Ovarian Cancer at SITC 2024

HOLON, ISRAEL, Nov. 5, 2024 -- Compugen Ltd., a clinical-stage company specializing in cancer immunotherapy, recently disclosed findings that highlight the efficacy and safety of a triple combination treatment involving COM701, COM902, and pembrolizumab in patients with advanced platinum-resistant ovarian cancer. This data was shared as an abstract by the Society for Immunotherapy of Cancer (SITC).

Dr. Oladapo Yeku of Harvard Medical School and Massachusetts General Hospital, who was an investigator in the study, will present these findings at SITC's 39th Annual Meeting in Houston, Texas, from November 8-10, 2024. Dr. Yeku emphasized the promising results, showing that COM701, when administered with COM902 and pembrolizumab, elicited durable and objective responses in late-stage ovarian cancer patients who typically do not respond well to other immunotherapies. He underscored the significant need for effective and tolerable treatments for relapsed ovarian cancer patients and expressed his optimism about further clinical development of COM701.

Anat Cohen-Dayag, Ph.D., President, and CEO of Compugen, echoed this optimism, noting the consistency of the data across studies involving more than forty heavily pre-treated patients. According to Dr. Cohen-Dayag, the evidence supports the unique mechanism of action of COM701, which appears to translate into clinical benefits for ovarian cancer patients. She also highlighted the potential to advance COM701 to earlier stages of ovarian cancer therapy, particularly for those who respond to chemotherapy but cannot continue with additional maintenance treatments due to a less compromised immune system. This could potentially improve progression-free survival rates for these patients.

Compugen, leveraging its computational discovery platform UnigenTM, focuses on identifying novel drug targets and pathways for cancer immunotherapies. The company has developed two proprietary products: COM701, an anti-PVRIG antibody, and COM902, an anti-TIGIT antibody, both of which are in Phase 1 development for solid tumors. Additionally, a PD-1/TIGIT bispecific antibody derived from COM902, known as rilvegostomig, is in Phase 3 development by AstraZeneca under a licensing agreement. Compugen's pipeline also includes early-stage immuno-oncology programs such as COM503, an anti-IL-18 binding protein antibody, which is licensed to Gilead and has been granted IND clearance by the FDA.

Compugen is based in Israel and operates an office in San Francisco, CA. Its shares are publicly traded on Nasdaq and the Tel Aviv Stock Exchange under the symbol CGEN.

The abstract detailing these findings is now available on Compugen's website, and additional materials, including a poster and a short video presentation by Dr. Yeku, will be accessible on November 8, 2024. Dr. Cohen-Dayag and Dr. Yeku will further discuss these results and future development plans during a fireside chat at Compugen's third-quarter conference call scheduled for November 12, 2024.